Stock Analysis on Net
Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Beginner level

Historical Valuation Ratios (Summary)

Edwards Lifesciences Corp., historical price multiples (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Price to earnings (P/E) 61.28 65.79 39.74 46.05 61.52 61.07 47.99 51.14 41.12 45.24 48.67 48.16 28.95 34.05 35.04 33.48 37.26 46.13 43.71 37.39
Price to operating profit (P/OP) 56.78 61.66 35.77 42.04 57.30 56.37 47.70 49.37 26.74 28.00 25.96 25.66 22.59 26.24 26.76 25.38 28.50 35.53 34.06 29.11
Price to sales (P/S) 11.14 11.32 9.82 11.09 11.46 11.17 9.61 9.92 8.06 8.37 7.91 8.18 6.51 7.55 7.31 6.43 7.17 8.89 8.65 7.42
Price to book value (P/BV) 11.56 12.74 11.29 11.62 12.48 12.65 10.65 11.76 8.72 9.39 8.40 9.51 6.82 8.30 8.39 7.28 7.64 9.86 9.78 7.39 6.90 7.22 6.31

Based on: 10-Q (filing date: 2020-10-26), 10-Q (filing date: 2020-07-27), 10-Q (filing date: 2020-04-28), 10-K (filing date: 2020-02-14), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-27), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-29), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-29), 10-Q (filing date: 2015-07-29), 10-Q (filing date: 2015-04-29).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Edwards Lifesciences Corp.’s P/E ratio increased from Q1 2020 to Q2 2020 but then slightly decreased from Q2 2020 to Q3 2020.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Edwards Lifesciences Corp.’s P/OP ratio increased from Q1 2020 to Q2 2020 but then slightly decreased from Q2 2020 to Q3 2020.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Edwards Lifesciences Corp.’s P/S ratio increased from Q1 2020 to Q2 2020 but then slightly decreased from Q2 2020 to Q3 2020.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Edwards Lifesciences Corp.’s P/BV ratio increased from Q1 2020 to Q2 2020 but then slightly decreased from Q2 2020 to Q3 2020 not reaching Q1 2020 level.

Price to Earnings (P/E)

Edwards Lifesciences Corp., historical P/E calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
No. shares of common stock outstanding1 623,248,273 621,740,581 619,664,253 627,367,734 625,710,042 623,907,657 625,504,809 623,298,987 627,147,807 628,157,934 632,337,345 630,071,124 634,859,673 633,474,090 629,408,397 637,487,394 641,441,817 638,636,484 635,288,220 643,792,782 647,128,974 645,093,966 645,346,434
Selected Financial Data (US$)
Net income (loss) (in thousands) 325,200  (121,900) 310,600  280,200  274,700  242,300  249,700  7,000  225,900  282,700  206,600  (2,800) 170,100  186,100  230,200  158,500  141,400  126,600  143,000  140,700  118,100  112,700  123,400 
Earnings per share (EPS)2 1.27 1.20 1.79 1.67 1.24 1.16 1.22 1.16 1.14 1.05 0.89 0.93 1.17 1.13 1.04 0.89 0.86 0.83 0.81 0.77 0.00 0.00 0.00
Share price1, 3 78.08 78.69 71.05 76.85 76.07 70.95 58.71 59.26 46.71 47.29 43.10 44.61 33.97 38.50 36.56 29.91 32.05 38.17 35.40 28.74 25.83 25.63 21.66
Valuation Ratio
P/E ratio4 61.28 65.79 39.74 46.05 61.52 61.07 47.99 51.14 41.12 45.24 48.67 48.16 28.95 34.05 35.04 33.48 37.26 46.13 43.71 37.39
Benchmarks
P/E Ratio, Competitors5
Becton, Dickinson & Co. 95.62 75.45 90.00 65.09 83.38 66.87 72.88 408.36 105.60 206.04 49.63 59.56 30.05 28.94 36.65 32.09 43.18 41.64 45.52 38.75 27.56 24.05
Boston Scientific Corp. 13.56 11.72 11.86 51.90 42.77 28.42 33.06 73.07 89.21 363.19 354.70 44.70 46.56 83.30 96.19 362.11
Danaher Corp. 46.61 41.91 35.88 38.34 40.31 41.93 37.63 29.77 25.70 27.06 27.78 27.25 26.31 26.25 25.00 23.02 22.23 16.01 18.64 17.85
Intuitive Surgical Inc. 82.17 70.73 44.28 48.72 49.80 51.02 53.16 53.03 73.32 73.33 69.50 70.95 45.87 42.21 38.18 37.16 36.58 39.90 37.79 34.24
Medtronic PLC 25.38 31.86 32.75 28.78 25.11 57.38 41.16 37.80 37.82 21.55 26.35 29.96 28.24 23.20 32.64 33.17 43.49 47.09 37.49 40.56
Stryker Corp. 45.35 31.33 39.24 23.72 22.60 19.64 18.96 48.55 58.86 62.59 54.36 33.60 32.52 29.96 27.92 25.79 27.29 25.30 24.92
Thermo Fisher Scientific Inc. 44.19 35.50 33.36 33.89 31.08 35.11 35.19 36.71 39.27 37.52 37.66 33.39 30.36 30.83 30.45 29.02 31.09 29.03 26.19
UnitedHealth Group Inc. 16.88 19.91 20.48 17.79 17.98 17.93 21.09 21.18 20.91 20.02 20.77 23.90 23.24 22.18 21.73 20.76 22.06 20.88 18.18

Based on: 10-Q (filing date: 2020-10-26), 10-Q (filing date: 2020-07-27), 10-Q (filing date: 2020-04-28), 10-K (filing date: 2020-02-14), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-27), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-29), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-29), 10-Q (filing date: 2015-07-29), 10-Q (filing date: 2015-04-29).

1 Data adjusted for splits and stock dividends.

2 Q3 2020 Calculation
EPS = (Net income (loss)Q3 2020 + Net income (loss)Q2 2020 + Net income (loss)Q1 2020 + Net income (loss)Q4 2019) ÷ No. shares of common stock outstanding
= (325,200,000 + -121,900,000 + 310,600,000 + 280,200,000) ÷ 623,248,273 = 1.27

3 Closing price as at the filing date of Edwards Lifesciences Corp.’s Quarterly or Annual Report.

4 Q3 2020 Calculation
P/E ratio = Share price ÷ EPS
= 78.08 ÷ 1.27 = 61.28

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Edwards Lifesciences Corp.’s P/E ratio increased from Q1 2020 to Q2 2020 but then slightly decreased from Q2 2020 to Q3 2020.

Price to Operating Profit (P/OP)

Edwards Lifesciences Corp., historical P/OP calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
No. shares of common stock outstanding1 623,248,273 621,740,581 619,664,253 627,367,734 625,710,042 623,907,657 625,504,809 623,298,987 627,147,807 628,157,934 632,337,345 630,071,124 634,859,673 633,474,090 629,408,397 637,487,394 641,441,817 638,636,484 635,288,220 643,792,782 647,128,974 645,093,966 645,346,434
Selected Financial Data (US$)
Operating income (loss) (in thousands) 357,800  (169,700) 358,100  310,800  294,300  267,500  274,200  (5,300) 248,900  252,100  252,500  342,200  214,000  241,000  298,300  201,200  188,800  171,500  189,700  171,400  153,400  145,800  165,100 
Operating profit per share2 1.38 1.28 1.99 1.83 1.33 1.26 1.23 1.20 1.75 1.69 1.66 1.74 1.50 1.47 1.37 1.18 1.12 1.07 1.04 0.99 0.00 0.00 0.00
Share price1, 3 78.08 78.69 71.05 76.85 76.07 70.95 58.71 59.26 46.71 47.29 43.10 44.61 33.97 38.50 36.56 29.91 32.05 38.17 35.40 28.74 25.83 25.63 21.66
Valuation Ratio
P/OP ratio4 56.78 61.66 35.77 42.04 57.30 56.37 47.70 49.37 26.74 28.00 25.96 25.66 22.59 26.24 26.76 25.38 28.50 35.53 34.06 29.11
Benchmarks
P/OP Ratio, Competitors5
Becton, Dickinson & Co. 56.20 43.34 49.82 40.02 29.43 29.40 30.27 43.37 47.87 95.72 67.53 34.59 40.06 21.15 20.05 25.02 22.42 27.98 26.60 29.46 26.74 19.97 17.53
Boston Scientific Corp. 80.81 44.72 36.71 34.77 36.58 31.15 36.68 32.51 31.09 30.63 28.71 34.07 34.07 69.95 74.67 814.74
Danaher Corp. 46.28 43.09 35.22 34.47 29.97 30.85 26.85 23.18 20.95 21.72 22.58 22.48 22.35 21.13 20.83 21.37 18.48 18.09 19.87 17.27
Intuitive Surgical Inc. 83.88 71.30 43.68 48.89 50.00 49.12 51.89 49.87 48.90 50.69 46.82 44.40 41.74 35.53 31.07 28.93 28.50 31.46 30.10 27.24
Medtronic PLC 21.01 23.52 22.21 21.26 19.74 21.13 20.04 17.64 16.73 17.82 19.53 22.64 21.53 18.18 22.35 22.18 25.45 26.74 25.83 28.81
Stryker Corp. 33.20 24.04 30.13 32.94 33.22 27.96 26.55 23.52 25.45 27.41 24.21 26.70 25.11 22.99 21.23 19.87 21.42 20.73 19.27
Thermo Fisher Scientific Inc. 36.59 28.44 26.84 26.99 24.59 28.45 27.33 26.24 28.33 26.99 28.24 28.12 25.79 26.21 25.13 24.26 25.78 24.44 22.15
UnitedHealth Group Inc. 11.85 13.80 14.40 12.43 12.51 12.48 14.58 15.82 15.19 14.17 14.42 14.30 13.54 12.56 11.79 11.14 11.71 11.07 9.59

Based on: 10-Q (filing date: 2020-10-26), 10-Q (filing date: 2020-07-27), 10-Q (filing date: 2020-04-28), 10-K (filing date: 2020-02-14), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-27), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-29), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-29), 10-Q (filing date: 2015-07-29), 10-Q (filing date: 2015-04-29).

1 Data adjusted for splits and stock dividends.

2 Q3 2020 Calculation
Operating profit per share = (Operating income (loss)Q3 2020 + Operating income (loss)Q2 2020 + Operating income (loss)Q1 2020 + Operating income (loss)Q4 2019) ÷ No. shares of common stock outstanding
= (357,800,000 + -169,700,000 + 358,100,000 + 310,800,000) ÷ 623,248,273 = 1.38

3 Closing price as at the filing date of Edwards Lifesciences Corp.’s Quarterly or Annual Report.

4 Q3 2020 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 78.08 ÷ 1.38 = 56.78

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Edwards Lifesciences Corp.’s P/OP ratio increased from Q1 2020 to Q2 2020 but then slightly decreased from Q2 2020 to Q3 2020.

Price to Sales (P/S)

Edwards Lifesciences Corp., historical P/S calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
No. shares of common stock outstanding1 623,248,273 621,740,581 619,664,253 627,367,734 625,710,042 623,907,657 625,504,809 623,298,987 627,147,807 628,157,934 632,337,345 630,071,124 634,859,673 633,474,090 629,408,397 637,487,394 641,441,817 638,636,484 635,288,220 643,792,782 647,128,974 645,093,966 645,346,434
Selected Financial Data (US$)
Net sales (in thousands) 1,140,900  925,000  1,128,700  1,174,100  1,094,000  1,086,900  993,000  977,700  906,600  943,700  894,800  888,500  821,500  841,800  883,500  767,700  739,400  759,300  697,300  671,100  615,500  616,800  590,300 
Sales per share2 7.01 6.95 7.24 6.93 6.64 6.35 6.11 5.97 5.79 5.65 5.45 5.45 5.22 5.10 5.00 4.65 4.47 4.30 4.09 3.87 0.00 0.00 0.00
Share price1, 3 78.08 78.69 71.05 76.85 76.07 70.95 58.71 59.26 46.71 47.29 43.10 44.61 33.97 38.50 36.56 29.91 32.05 38.17 35.40 28.74 25.83 25.63 21.66
Valuation Ratio
P/S ratio4 11.14 11.32 9.82 11.09 11.46 11.17 9.61 9.92 8.06 8.37 7.91 8.18 6.51 7.55 7.31 6.43 7.17 8.89 8.65 7.42
Benchmarks
P/S Ratio, Competitors5
Becton, Dickinson & Co. 4.45 4.00 3.94 4.07 3.82 3.64 3.82 4.06 4.45 4.49 4.94 4.23 3.72 3.21 3.05 2.87 2.97 2.86 2.55 3.08 3.35 3.51 3.26
Boston Scientific Corp. 5.31 4.66 5.19 5.44 5.92 5.14 5.62 5.06 4.89 4.39 4.08 4.27 4.21 4.22 3.98 3.59 4.08 3.86 3.13
Danaher Corp. 8.15 7.48 6.34 6.29 5.32 5.43 4.67 3.97 3.62 3.74 3.77 3.70 3.52 3.32 3.35 3.48 3.05 2.94 3.34 2.91
Intuitive Surgical Inc. 20.09 18.44 13.33 15.01 15.41 15.28 15.83 16.06 16.36 17.01 16.16 14.96 13.83 12.01 10.69 10.11 10.06 10.69 9.70 8.46
Medtronic PLC 4.34 4.82 4.72 4.36 4.04 4.27 4.35 3.92 3.57 3.65 3.62 4.06 3.82 3.39 4.14 4.07 3.70 4.20 4.23 5.36
Stryker Corp. 5.16 4.53 5.49 5.59 5.65 4.98 4.95 4.52 4.88 5.01 4.46 4.93 4.62 4.29 4.06 3.93 4.18 4.07 3.61
Thermo Fisher Scientific Inc. 6.24 5.08 4.83 4.83 4.43 4.52 4.24 3.95 4.07 3.84 4.01 3.92 3.58 3.57 3.37 3.22 3.53 3.34 3.05
UnitedHealth Group Inc. 1.17 1.12 1.18 1.00 1.00 0.98 1.12 1.22 1.17 1.09 1.10 1.05 0.98 0.89 0.83 0.75 0.78 0.76 0.68

Based on: 10-Q (filing date: 2020-10-26), 10-Q (filing date: 2020-07-27), 10-Q (filing date: 2020-04-28), 10-K (filing date: 2020-02-14), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-27), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-29), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-29), 10-Q (filing date: 2015-07-29), 10-Q (filing date: 2015-04-29).

1 Data adjusted for splits and stock dividends.

2 Q3 2020 Calculation
Sales per share = (Net salesQ3 2020 + Net salesQ2 2020 + Net salesQ1 2020 + Net salesQ4 2019) ÷ No. shares of common stock outstanding
= (1,140,900,000 + 925,000,000 + 1,128,700,000 + 1,174,100,000) ÷ 623,248,273 = 7.01

3 Closing price as at the filing date of Edwards Lifesciences Corp.’s Quarterly or Annual Report.

4 Q3 2020 Calculation
P/S ratio = Share price ÷ Sales per share
= 78.08 ÷ 7.01 = 11.14

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Edwards Lifesciences Corp.’s P/S ratio increased from Q1 2020 to Q2 2020 but then slightly decreased from Q2 2020 to Q3 2020.

Price to Book Value (P/BV)

Edwards Lifesciences Corp., historical P/BV calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
No. shares of common stock outstanding1 623,248,273 621,740,581 619,664,253 627,367,734 625,710,042 623,907,657 625,504,809 623,298,987 627,147,807 628,157,934 632,337,345 630,071,124 634,859,673 633,474,090 629,408,397 637,487,394 641,441,817 638,636,484 635,288,220 643,792,782 647,128,974 645,093,966 645,346,434
Selected Financial Data (US$)
Stockholders’ equity (in thousands) 4,210,300  3,839,100  3,901,100  4,148,300  3,814,800  3,500,300  3,447,500  3,140,400  3,361,300  3,164,200  3,245,700  2,956,200  3,162,500  2,939,600  2,742,700  2,619,000  2,691,800  2,471,200  2,299,300  2,503,100  2,421,400  2,288,600  2,213,900 
Book value per share (BVPS)2 6.76 6.17 6.30 6.61 6.10 5.61 5.51 5.04 5.36 5.04 5.13 4.69 4.98 4.64 4.36 4.11 4.20 3.87 3.62 3.89 3.74 3.55 3.43
Share price1, 3 78.08 78.69 71.05 76.85 76.07 70.95 58.71 59.26 46.71 47.29 43.10 44.61 33.97 38.50 36.56 29.91 32.05 38.17 35.40 28.74 25.83 25.63 21.66
Valuation Ratio
P/BV ratio4 11.56 12.74 11.29 11.62 12.48 12.65 10.65 11.76 8.72 9.39 8.40 9.51 6.82 8.30 8.39 7.28 7.64 9.86 9.78 7.39 6.90 7.22 6.31
Benchmarks
P/BV Ratio, Competitors5
Becton, Dickinson & Co. 3.13 3.32 3.23 3.34 3.04 2.91 3.05 3.09 3.07 2.87 2.85 3.95 3.60 4.96 4.99 4.69 4.55 4.56 3.97 4.42 4.35 4.15 5.46
Boston Scientific Corp. 3.46 3.64 4.02 5.83 6.33 5.53 6.33 5.91 6.00 5.79 5.26 4.97 5.07 5.14 4.96 4.52 5.22 4.58 3.70 3.92 3.56 3.57
Danaher Corp. 4.38 3.90 3.68 3.72 3.02 3.19 2.88 2.80 2.56 2.65 2.61 2.58 2.47 2.35 2.42 2.56 2.39 2.24 2.70 2.53 2.79 2.53 2.57
Intuitive Surgical Inc. 9.35 9.19 7.22 8.13 8.43 8.49 8.68 8.96 9.30 10.03 9.71 9.91 8.35 7.62 7.21 4.73 4.77 5.22 5.00 4.67 4.53 5.37 5.31
Medtronic PLC 2.60 2.94 2.87 2.66 2.48 2.62 2.59 2.31 2.11 2.10 2.14 2.40 2.27 1.96 2.34 2.25 2.08 2.09 1.86 2.04 3.79 3.72 3.25
Stryker Corp. 5.69 5.17 6.38 6.60 6.72 5.92 5.74 6.09 6.72 6.92 5.56 5.73 5.51 5.21 4.82 4.59 4.81 4.65 4.21 4.18 4.52 4.19
Thermo Fisher Scientific Inc. 5.48 4.56 4.16 4.15 3.83 4.02 3.75 3.51 3.55 3.24 3.30 3.14 3.07 3.07 2.86 2.67 2.92 2.76 2.42 2.50 2.69 2.55
UnitedHealth Group Inc. 4.53 4.81 4.92 4.32 4.40 4.37 4.89 5.32 5.13 4.72 4.59 4.55 4.37 4.01 3.98 3.61 3.75 3.57 3.12 3.35 3.51 3.39

Based on: 10-Q (filing date: 2020-10-26), 10-Q (filing date: 2020-07-27), 10-Q (filing date: 2020-04-28), 10-K (filing date: 2020-02-14), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-27), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-29), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-29), 10-Q (filing date: 2015-07-29), 10-Q (filing date: 2015-04-29).

1 Data adjusted for splits and stock dividends.

2 Q3 2020 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 4,210,300,000 ÷ 623,248,273 = 6.76

3 Closing price as at the filing date of Edwards Lifesciences Corp.’s Quarterly or Annual Report.

4 Q3 2020 Calculation
P/BV ratio = Share price ÷ BVPS
= 78.08 ÷ 6.76 = 11.56

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Edwards Lifesciences Corp.’s P/BV ratio increased from Q1 2020 to Q2 2020 but then slightly decreased from Q2 2020 to Q3 2020 not reaching Q1 2020 level.